SCHEMBL5026165

SCHEMBL5026165

NC(=O)c1sc2nc(-c3ccco3)nc(-c3cccc(N)c3)c2c1N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 1/20 0.60
BRAF P15056 8/20 0.58
PDE4A P27815 5/20 0.58
PDE4B Q07343 5/20 0.58
PDE4C Q08493 5/20 0.58
PDE4D Q08499 5/20 0.58
IKBKB O14920 2/20 0.57
MAPT P10636 3/20 0.50
USP2 O75604 1/20 0.50
HTT P42858 1/20 0.50
PTK2B Q14289 1/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
EEF2K O00418 6/20 0.49
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5026962 0.92 LIMK1 (0.53) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL5024691 0.86 LHCGR (0.57) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL5026123 0.86 KDM4E (0.54) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL4419064 0.85 BRAF (0.64) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL5024656 0.84 LIMK1 (0.52) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL5030909 0.82 BRAF (0.61) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL5026126 0.80 BRAF (0.59) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL6110282 0.79 IKBKB (0.68) LIMK1IKBKBMAPTUSP2HTT
SCHEMBL27536473 0.79 LIMK1 (0.48) LIMK1PDE4APDE4BPDE4CPDE4D
SCHEMBL5030956 0.79 BRAF (0.47) LIMK1BRAFPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7375109-B2 Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity N.V. ORGANON (NL) 2008-05-20 US disclosed
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity MERCK SHARP & DOHME B.V. (NL) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity FSHR, GNRHR, LHCGR LIMK1 4850/4885BRAF 4677/4885PDE4A 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.